Because the aberrant activation of the EMT process enhanced malignant progression (including metastasis, invasion, and chemoresistance) of various kinds of cancer cells (Girisa et al., 2021; Cook and Wrana, 2022), to evaluate the association of CNTN-1 with malignant progression via EMT, the wound-healing assay, invasion assay, and drug sensitivity assay were carried out and the data showed that CNTN-1 overexpression dramatically enhanced the migration (Figure 5A), invasion (Figure 5B), and tolerance to cisplatin (A549-CNTN-1 vs. A549-CNTN-1-NC, Figure 5C). Here, CNTN1 is linked to cancer.